LAVAL, QUEBEC--(Marketwired - May 9, 2013) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF) ("ProMetic" or the "Corporation") today reported pursuant to new regulatory disclosure obligations that all nominees listed in the management proxy circular dated March 22, 2013 were elected as directors of ProMetic at its annual and special meeting of shareholders (AGM) held on May 8, 2013 in Montreal (Quebec).
According to the proxies, a total of 145,176,247 Common shares were voted at the meeting, representing 29.80% of the votes attached to all outstanding shares. Shareholders voted in favor of all items of business, including the election of all director nominees as follows:
| Nominee | votes For | % votes For | votes Withheld | % votes Withheld |
| G.F. Kym Anthony | 132,811,405 | 99.15 | 1,132,610 | 0.85 |
| Michael J. Brunelle | 132,762,350 | 99.12 | 1,181,665 | 0.88 |
| Raymond M. Hakim | 132,790,750 | 99.14 | 1,153,265 | 0.86 |
| Robert Lacroix | 131,931,255 | 98.50 | 2,012,760 | 1.50 |
| Pierre Laurin | 132,968,910 | 99.27 | 975,105 | 0.73 |
| Louise Ménard | 132,289,305 | 98.76 | 1,654,710 | 1.24 |
| Paul Mesburis | 132,961,905 | 99.27 | 982,110 | 0.73 |
| John Moran | 132,789,505 | 99.14 | 1,154,510 | 0.86 |
| Nancy Orr | 131,982,200 | 98.54 | 1,961,815 | 1.46 |
| Bruce Wendel | 130,124,550 | 97.15 | 3,819,465 | 2.85 |
| Benjamin Wygodny | 132,772,450 | 99.13 | 1,171,565 | 0.87 |
The directors were elected to hold offices until the next annual meeting of shareholders or until their successors are elected or appointed. Detailed voting results for the meeting are available on SEDAR at www.sedar.com .
New Directors Elected
Dr. Hakim served as Chief Medical Officer and Senior Executive Vice President, Clinical & Scientific Affairs for Fresenius Medical Services North America. Dr. Hakim completed his Nephrology fellowship at Harvard Medical School and at Brigham and Women's Hospital in Boston. He went on to serve as Medical Director of Dialysis Clinical Services at Vanderbilt University Hospital. In 1995, Dr. Hakim became one of the founders of Renal Care Group which later merged with Fresenius Medical Care North America.
Dr Hakim is joining existing Director, Dr. John Moran to support the advancement of ProMetic's lead drug candidates for the treatment of Chronic Kidney Diseases.
Michael J. Brunelle currently serves as Vice President of Development for NantWorks and Affiliated Organizations. Mr. Brunelle serves on the board of directors for Strand Diagnostics, Expression Pathology and Dithera. Mr. Brunelle has over 30 years of health care experience as a consultant, investment banker and entrepreneur.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") ( www.prometic.com ) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Laval (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward -looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in ProMetic's Annual Information Form for the year ended December 31, 2012, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
